Printer Friendly

BIO-VASCULAR ANNOUNCES FDA APPROVAL FOR NEW PRODUCT

 ST. PAUL, Minn., Jan. 18 /PRNewswire/ -- Bio-Vascular, Inc. (NASDAQ: BVAS) has received approval from the U.S. Food and Drug Administration (FDA) to market Supple Peri-Guard(R) Pericardium, a new product, the company announced today.
 Supple Peri-Guard is a flexible tissue patch manufactured from bovine pericardium. It has been aolapses and defects of the abdominal or thoracic wall.
 John H. Darnall, Jr., president and chief executive officer, said that Supple Peri-Guard was developed at the request of surgeons who prefer a flexible material for some patching applications. For a number of years, the company has marketed Peri-Guard(R) Processed Bovine Pericardium, a similar but more rigid tissue patch.
 Bio-Vascular, Inc., based in St. Paul, is a manufacturer and marketer of proprietary consumable medical products for cardiac and vascular surgery.
 -0- 1/18/93
 /CONTACT: Curt Swenson of Swenson Falker Eilertsen, 612-371-0000, for Bio-Vascular; or John H. Darnall, Jr., or M. Karen Gilles of Bio-Vascular, 612-631-3529/
 (BVAS)


CO: Bio-Vascular, Inc. ST: Minnesota IN: MTC SU: PDT

AL -- MN006 -- 5937 01/18/93 14:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:174
Previous Article:McDONNELL DOUGLAS REALIGNS NON-AEROSPACE BUSINESSES WITH RETIREMENT OF GROUP EXECUTIVE
Next Article:ELECTRONIC ARTS ANNOUNCES FIRST $100 MILLION REVENUE QUARTER AND A 49 PERCENT INCREASE IN NET INCOME FOR ITS THIRD QUARTER
Topics:


Related Articles
BIO-VASCULAR WILL BEGIN CLINICAL TRIALS OF SMALL DIAMETER GRAFT
BIO-VASCULAR NAMES SCHANKERELI DIRECTOR OF RESEARCH AND DEVELOPMENT
BIO-VASCULAR DISCONTINUES CLINICAL TRIALS OF BIOFLOW GRAFT
VITAL IMAGES AGREES IN PRINCIPLE TO MERGER INTO BIO-VASCULAR, INC.
BIO-VASCULAR NAMES KEMAL SHANKERELI VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
BIO-VASCULAR RECEIVES FDA CLEARANCE TO MARKET PERI-GUARD PRODUCT FOR USE IN LUNG SURGERY
BIO-VASCULAR FILES FOR FDA CLEARANCE TO MARKET VASCU-GUARD PRODUCT FOR PERIPHERAL VASCULAR SURGERY
BIO-VASCULAR PROMOTES BRUCE A. MACFARLANE, PH.D., TO VICE PRESIDENT, REGULATORY AFFAIRS AND QUALITY ASSURANCE
Bio-Vascular Files With FDA For Ophthalmic Product
Bio-Vascular Files With FDA for Flo-Thru Intraluminal Shunt

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters